Pay in 4 interest-free payments of $5.48 Learn more
Ships within 48 hours · Estimated delivery Aug 16 - Aug 21
doi: 10.1152/ajprenal.00394.2015 101 ThomsonSCKashkouliASinghP
The 'Switch' is On: Proving the Viability of Oral Maintenance Therapy The ATTAIN-MAINTAIN study was a first-of-its-kind Phase 3 trial designed to answer a critical clinical question: can patients who have successfully lost weight on injectable GLP-1s (Wegovy or Zepbound) switch directly to an oral agent and maintain their results
NexLife is not affiliated with Novo Nordisk or Eli Lilly
Some weeks exceed expectations
US$ 20.65
US$ 20.26
US$ 29.67
US$ 27.65
US$ 27.75
US$ 29.34
